CHEK2

Serine/threonine-protein kinase Chk2

125,350 patent compounds predicted against CHEK2, 86,006 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hymenialdisine (SCHEMBL155899)	0.74	9/20
SCHEMBL217151	0.57	8/20
SCHEMBL184190	0.61	6/20
SCHEMBL183924	0.56	6/20
SCHEMBL183925	0.56	6/20
SCHEMBL183922	0.58	5/20
SCHEMBL183923	0.58	5/20
SCHEMBL183511	0.58	5/20
SCHEMBL183512	0.58	5/20
SCHEMBL184238	0.58	5/20
SCHEMBL183513	0.54	5/20
SCHEMBL184030	0.50	5/20
SCHEMBL184031	0.50	5/20
SCHEMBL104879	0.32	5/20
SCHEMBL179156	0.67	4/20
SCHEMBL215874	0.65	4/20
SCHEMBL184160	0.63	4/20
SCHEMBL184161	0.63	4/20
SCHEMBL183858	0.59	4/20
SCHEMBL183859	0.59	4/20

Germline variants in CHEK2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CHEK2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CHEK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis	PHASE2	ACTIVE_NOT_RECRUITING
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.	PHASE2	WITHDRAWN
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations	PHASE2	RECRUITING
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)	PHASE2	RECRUITING
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects	PHASE1/PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations	PHASE2	COMPLETED
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd	PHASE2	COMPLETED
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation	PHASE2	RECRUITING
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy	PHASE2	COMPLETED
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer	PHASE1/PHASE2	COMPLETED
Niraparib and Dostarlimab in HRD Solid Tumors	PHASE2	UNKNOWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors	PHASE1	RECRUITING
Tabectedin to Treat Children and Adolescents With Cancer	PHASE1	COMPLETED
A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
M6620 Plus Standard Treatment in Oesophageal and Other Cancer	PHASE1	COMPLETED
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	PHASE1	COMPLETED
DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy	nan	RECRUITING
Analysis of Tumors From Patients With Inherited Cancers Having Had Two Surgeries (Primary + Recurrent, or 2 Separate Types of Cancer)	nan	COMPLETED
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CHEK2 binder may also engage these)

Protein	Name	Similarity
Q9Z265	—	1.000	Q9Z265 →
CAMK1D	Calcium/calmodulin-dependent protein kinase type 1D	0.982	landscape →
Q8WP15	—	0.981	Q8WP15 →
Q8BW96	—	0.980	Q8BW96 →
Q28GW8	—	0.979	Q28GW8 →
Q6PFQ0	—	0.979	Q6PFQ0 →
O61267	—	0.979	O61267 →
Q91821	—	0.979	Q91821 →
Q5R4K3	—	0.978	Q5R4K3 →
P62205	—	0.978	P62205 →
PRKCA	Protein kinase C alpha type	0.978	landscape →
O55173	—	0.978	O55173 →
Q852Q2	—	0.978	Q852Q2 →
O54863	—	0.978	O54863 →
Q8C050	—	0.977	Q8C050 →
O61661	—	0.977	O61661 →
Q9JI10	—	0.977	Q9JI10 →
Q5F3L1	—	0.977	Q5F3L1 →
P13234	—	0.976	P13234 →
O54785	—	0.976	O54785 →
PRKCB	Protein kinase C beta type	0.976	landscape →
J9W0G9	—	0.976	J9W0G9 →
P13678	—	0.976	P13678 →
RPS6KA1	Ribosomal protein S6 kinase alpha-1	0.976	landscape →
RPS6KA5	Ribosomal protein S6 kinase alpha-5	0.976	landscape →
Q622Z7	—	0.976	Q622Z7 →
PLK2	Serine/threonine-protein kinase PLK2	0.976	landscape →
PRKCE	Protein kinase C epsilon type	0.976	landscape →
Q5R4L1	—	0.976	Q5R4L1 →
MELK	Maternal embryonic leucine zipper kinase	0.976	landscape →